Displaying 1881 - 1900 of 2293
FTC Puts Conditions on Coca-Cola's $12.3 Billion Acquisition of its Largest North American Bottler
Dun & Bradstreet Settles FTC Charges that 2009 Acquisition was Anticompetitive
FTC, HHS Office of Inspector General, and Centers for Medicare & Medicaid Services Announce Workshop on Issues Related to Accountable Care Organizations
Commission Proposes Changes to Improve Premerger Notification Form; Commission Approves Carilion Clinics Application to Sell the Center for Advanced Imaging to InSight Health Corp.
FTC Order Requires Tops Markets to Sell Seven Penn Traffic Supermarkets
FTC Approves Solvay's Application to Terminate Supply Agreement with Alventia; FTC Seeks Public Comments on Application by Dow Chemical Company to Modify Contract with Arkema Inc.
FTC Order Restores Competition in U.S. Markets for Herbicide Products
Fidelity National Financial Settles FTC Charges that its Acquisition of LandAmerica Subsidiaries Reduced Competition in Title Information Markets
Houghton International Agrees to Sell Aluminum Production Assets to Settle Charges that 2008 Acquisition of Stuart was Anticompetitive
FTC Approves Final Settlement Regarding Agilent Technologies' Proposed Acquisition of Varian
FTC Contributes Report to White House Council on Women and Girls
FTC Order Preserves Competition Threatened by Agilent's Acquisition of Varian
FTC Seeks Public Comments on Solvays Application to Terminate Supply Agreement with Alventia
FTC Provides Comments to FCC on Protecting Children in Traditional and New Media Environments; FTC Approves Final Settlement Order Regarding The M Group, Inc., Doing Business As Bamboosa; FTC Approves Final Settlement Order Regarding Roaring Fork Valley
FTC Order Preserves Competition That Would Have Been Eliminated by SCI's Acquisition of Keystone North America Inc.
Administrative Law Judge Rules That Polypore International's 2008 Acquisition of Rival Battery Separator Manufacturer Violated Antitrust Law
FTC Approves Final Consent Order in Case of Pfizer Inc. and Wyeth
Watson Pharmaceuticals, Inc., a corporation, and Robin Hood Holdings Limited, a limited liability company, In the Matter of
The Commission charged that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson’s disease (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission’s order requires the firms to sell assets related to the two drugs to FTC-approved buyers and to ensure the acquirers have the means to compete effectively in the future.
There is a related federal proceeding and two related administrative proceedings:
Displaying 1881 - 1900 of 2293